NCT05153772 - Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions

Neuroendocrine Tumors

Interventions

DRUG

AlphaMedix

212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors

Trial Locations (4)

Moffitt Cancer Center, Tampa

Louisiana State University (LSU) Health Sciences Center - New Orleans, Metairie

Excel Diagnostics and Nuclear Oncology Center, Houston

Rocky Mountain Cancer Center, Denver